Jane Street’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jane Street’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,982	Closed	-$622K	–	11297
2025 Q3	$582K	Sell	13,982 -89,314	-86%	-$2.86M	﹤0.01%	7526
2025 Q2	$2.97M	Buy	+103,296	New	+$3.19M	﹤0.01%	3772
2025 Q1	–	Sell	-7,404	Closed	-$277K	–	9579
2024 Q4	$379K	Sell	7,404 -122,188	-94%	-$6.84M	﹤0.01%	7327
2024 Q3	$6.62M	Buy	129,592 +9,712	+8%	+$501K	﹤0.01%	2423
2024 Q2	$5.37M	Buy	119,880 +82,956	+225%	+$3.83M	﹤0.01%	2871
2024 Q1	$1.73M	Sell	36,924 -66,110	-64%	-$2.59M	﹤0.01%	4390
2023 Q4	$3.67M	Buy	103,034 +90,222	+704%	+$2.77M	﹤0.01%	3321
2023 Q3	$381K	Sell	12,812 -9,308	-42%	-$192K	﹤0.01%	6682
2023 Q2	$399K	Buy	+22,120	New	+$441K	﹤0.01%	6665
2022 Q2	–	Sell	-14,936	Closed	-$328K	–	9783
2022 Q1	$328K	Buy	+14,936	New	+$302K	﹤0.01%	8262
2020 Q3	–	Sell	-18,194	Closed	-$319K	–	7221
2020 Q2	$319K	Buy	+18,194	New	+$310K	﹤0.01%	5749

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Jane Street's CRNX Position: Q4 2025 in Review

Jane Street sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2025, closing a stake of 13,982 shares — an estimated $622K sold.

Jane Street first reported a position in CRNX in Q2 2020 and held it in 11 quarters. The position peaked at $6.62M in Q3 2024. 240 funds tracked by Wall St. Rank hold CRNX as of Q4 2025.

Jane Street reported no remaining Crinetics Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Jane Street sold 13,982 Crinetics Pharmaceuticals shares in Q4 2025, an estimated $622K.
Jane Street first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 11 quarters.
Jane Street's Crinetics Pharmaceuticals position peaked at $6.62M in Q3 2024.
240 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.